A phase 2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Fudan University, now recruiting.
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06196788 by Fudan University, with a registry enrolment figure of 30 participants, started 2024-03-01 and due to reach its primary completion in 2026-03-01. Interventions recorded: Gemcitabine; Nab paclitaxel. Conditions listed: Pancreatic Cancer. Primary outcome: Overall survival,OS. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreas adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.